Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Reset filter

Keywords

Hypertension ×

Clinical Trial (414)
Eligibility Determination (412)
Cardiology (355)
Pharmacokinetics (43)
On-Study Form (24)
Cross-Over Studies (19)
Clinical Trial, Phase I (17)
Drugs, Investigational (12)
Vital Signs (11)
Drug trial (11)
End of Study (10)
Treatment Form (9)
Electrocardiogram (ECG) (9)
Outcome Assessment (Health Care) (6)
Blood Pressure (6)
Adverse event (6)
Scores & Instruments (6)
Released Standard (6)
Alcohol Drinking (6)
Lisinopril (5)
Concomitant Medication (5)
Blood (4)
Comparative Study (4)
Follow-Up Studies (4)
Laboratories (4)
Pharmacogenetics (3)
Pregnancy (3)
Patient Reported Outcome (PRO) (3)
Trial screening (3)
Clinical Protocols (3)
Demography (3)
Diet (3)
Medical Records (3)
Pressure (2)
Annual Reports (2)
Breast Neoplasms (2)
Consent Forms (2)
Drug-Related Side Effects and Adverse Reactions (2)
Baseline (2)
Pre-Study Form (2)
EHR (2)
Routine documentation (2)
Diabetes Mellitus (2)
Heart Rate (2)
Informed Consent (2)
Myocardial Infarction (2)
Nephrology (2)
Pre-Eclampsia (1)
Pregnancy Tests (1)
Random Allocation (1)
Research Personnel (1)
Risk Factors (1)
Atrial Fibrillation (1)
Smoking (1)
Telemetry (1)
Vascular Diseases (1)
Electrocardiography, Ambulatory (1)
Randomized Controlled Trial (1)
Abnormalities, Multiple (1)
African Americans (1)
Case Management (1)
Stroke (1)
Metabolic Syndrome X (1)
Pulmonary Disease, Chronic Obstructive (1)
Research Subjects (1)
Endothelial Cells (1)
African Continental Ancestry Group (1)
European Continental Ancestry Group (1)
Asian Continental Ancestry Group (1)
Oceanic Ancestry Group (1)
Continental Population Groups (1)
Postpartum Period (1)
Atherosclerosis (1)
Prehypertension (1)
Cholesterol (1)
Pulmonary Arterial Hypertension (1)
Diabetes (1)
Coronary Disease (1)
Diabetes Mellitus, Type 2 (1)
Diuretics (1)
DNA (1)
Drug Administration Schedule (1)
Electrocardiography (1)
Endocrinology (1)
Heart Diseases (1)
Heart Failure (1)
Erectile Dysfunction (1)
Kidney Diseases (1)
Lung Neoplasms (1)
Medical History Taking (1)
Antihypertensive Agents (1)
Obesity (1)
Organization and Administration (1)

Show more Keywords

Select data models

Selected data models

You must log in to select data models for download or further analysis.

482 Search results.

dbGaP phs000297 eMERGE Network Study of Resistant Hypertension - Eligibility

- 6/23/22 - 5 forms, 1 itemgroup, 9 items, 1 language

Itemgroup: IG.elig

Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Hypertension https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000297 The **e**lectronic **M**edical **R**ecords and **Ge**nomics (eMERGE) Network is a consortium of five participating sites (Group Health Seattle, Marshfield Clinic, Mayo Clinic, Northwestern University, and Vanderbilt University) funded by the NHGRI to investigate the use of electronic medical record systems for genomic research. The goal of eMERGE is to conduct genome-wide association studies in approximately 19,000 individuals using EMR-derived phenotypes and DNA from linked Biorepositories. Using electronic phenotyping methods, the consortium used DNA samples from all participating sites to explore the genetic determinants of resistant hypertension. Treatment resistant hypertension is a common health problem in the clinical setting. A basic definition of resistant hypertension included subjects with uncontrolled blood pressure despite use of three antihypertensive medications or subjects requiring four or more medications to maintain control. Other conditions, such as secondary causes of hypertension, were exclusions. Site and participants include: *Vanderbilt University*: BioVU, Vanderbilt's DNA databank, is an enabling resource for exploration of the relationships among genetic variation, disease susceptibility, and variable drug responses, and represents a key first step in moving the emerging sciences of genomics and pharmacogenomics from research tools to clinical practice. BioVU acquires DNA from discarded blood samples collected from routine patient care. The biobank is linked to de-identified clinical data extracted from Vanderbilt's EMR, which forms the basis for phenotype definitions used in genotype-phenotype correlations. *Marshfield Clinic*: The Marshfield Clinic Personalized Medicine Research Project is a population-based biobank in central Wisconsin with more than 20,000 adult subjects who provided written, informed consent to access their medical records and provided a blood sample from which DNA was extracted and plasma and serum stored. In addition to an average of 30 years of medical history data, a questionnaire about environmental exposures, including a detailed food frequency questionnaire, is available to facilitate gene/environment studies. *Northwestern University*: The NUgene Project is a repository with longitudinal medical information from participating patients at affiliated hospitals and outpatient clinics from the Northwestern University Medical Center. Participants' DNA samples are coupled with data from a self-reported questionnaire and continuously updated data from our Electronic Medical Record (EMR) representing actual clinical care events. Northwestern has a state-of-the art, comprehensive inpatient and outpatient EMR system of over 2 million patients. NUgene has broad access to participant data for all outpatient visits as well as inpatient data via a consolidated data warehouse. NUgene participants consent to distribution and use of their coded DNA samples and data for a broad range of genetic research by third-party investigators. *Group Health(GH)/University of Washington (UW)*: Aging and Dementia eMERGE study biorepository leverages rich population-based longitudinal data from both electronic medical records and in-depth research data to explore genome wide associations. Participants include Seattle-area members of GH (a large integrated health care system in Washington State) consented and enrolled in 1) the UW Alzheimer's Disease Patient Registry (ADPR) and 2) the Adult Changes in Thought (ACT) study. The ADPR (PI: Eric B. Larson; NIH/NIA U01 AG 006781) is a population-based registry of incident dementia cases designed to identify all new Alzheimer's Disease cases within GH from 1987 to 1996. Medical history, physical, laboratory testing, and neuropsychological testing were performed on all consenting potential cases for determination of dementia status by a consensus conference. The study base of the ADPR population was stable with an attrition rate of less than 1%/year. The ACT study (PI: Eric B. Larson; NIH/NIA U01 AG 006781) is an ongoing community-based cohort study of aging and dementia. The original cohort of 2,581 randomly selected dementia-free members age 65 and older was enrolled in 1994-1996 and expanded by 811 in 2000-2002. Continuous enrollment to maintain a cohort of 2,000 dementia free persons began in 2005. Participants receive biennial assessment including cognitive status determination. The ACT sub-sample is stable; for the original cohort, median enrollment in GH was 19 years prior to joining the ACT study, and 85% of the cohort has ≥ 10 years of GH enrollment. DNA for the ADPR participants were obtained through a companion study, Genetic Differences in Cases and Controls (PI: Walter Kukull; NIH/NIA R01 AG007584). DNA obtained through both studies were extracted from blood using Gentra Systems Puregene methods. DNA concentration is determined by UV optical density. All samples are checked for quality by 260/280 ratio. For long-term storage, samples are aliquoted and stored at -70°C. *Mayo Clinic*: The Mayo biobank is a disease-specific biobank for vascular diseases including peripheral arterial disease (PAD). PAD patients were identified from individuals referred to the non-invasive vascular laboratory for lower extremity arterial evaluation. Since 1997, laboratory findings have been recorded into an electronic database employing an in-house software package for data archiving and retrieval; this data becomes part of the Mayo EMR. Patients referred to the center with suspected PAD undergo a comprehensive non-invasive evaluation including the ankle-brachial index (ABI) - the ratio of blood pressure measured in the upper arms divided by blood pressure measured at the ankles. Controls subjects are identified from patients referred to the Cardiovascular Health Clinic for stress ECG. The prevalence of PAD in patients with normal exercise capacity who do not have inducible ischemia on the stress ECG, was 1%. Data regarding risk factors for atherosclerosis such as diabetes, dyslipidemia, hypertension, and smoking are ascertained from the EMR.

Hypertension

pht002391.v1.p1

1 itemgroup 5 items

pht002392.v1.p1

1 itemgroup 5 items

pht002393.v1.p1

1 itemgroup 13 items

dbGaP phs000090 The Atherosclerosis Risk in Communities (ARIC) Study - pht000114.v1.p1

- 5/23/22 - 3 forms, 1 itemgroup, 362 items, 1 language

Itemgroup: pht000114.v1.p1

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000090 The Atherosclerosis Risk in Communities (ARIC) Study, sponsored by the National Heart, Lung and Blood Institute (NHLBI), is a prospective epidemiologic study conducted in four U.S. communities. The four communities are Forsyth County, NC; Jackson, MS; the northwest suburbs of Minneapolis, MN; and Washington County, MD. ARIC is designed to investigate the etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic diseases, and variation in cardiovascular risk factors, medical care and disease by race, gender, location, and date. ARIC includes two parts: the Cohort Component and the Community Surveillance Component. The Cohort Component began in 1987, and each ARIC field center randomly selected and recruited a cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in their community. A total of 15,792 participants received an extensive examination, including medical, social, and demographic data. These participants were reexamined every three years with the first screen (baseline) occurring in 1987-89, the second in 1990-92, the third in 1993-95, and the fourth and last exam was in 1996-98. Follow-up occurs yearly by telephone to maintain contact with participants and to assess health status of the cohort. In the Community Surveillance Component, currently ongoing, these four communities are investigated to determine the community-wide occurrence of hospitalized myocardial infarction and coronary heart disease deaths in men and women aged 35-84 years. Hospitalized stroke is investigated in cohort participants only. Starting in 2006, the study conducts community surveillance of inpatient (ages 55 years and older) and outpatient heart failure (ages 65 years and older) for heart failure events beginning in 2005. ARIC is currently funded through January 31, 2012. This study is part of the Gene Environment Association Studies initiative (GENEVA, http://www.genevastudy.org) funded by the trans-NIH Genes, Environment, and Health Initiative (GEI). The overarching goal is to identify novel genetic factors that contribute to atherosclerosis and cardiovascular disease through large-scale genome-wide association studies of well-characterized cohorts of adults in four defined populations. Genotyping was performed at the Broad Institute of MIT and Harvard, a GENEVA genotyping center. Data cleaning and harmonization were done at the GEI-funded GENEVA Coordinating Center at the University of Washington.

pht001035.v1.p1

1 itemgroup 4 items